Edgestream Partners L.P. Increases Holdings in Masimo Co. (NASDAQ:MASI)

Edgestream Partners L.P. boosted its stake in shares of Masimo Co. (NASDAQ:MASI) by 103.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,449 shares of the medical equipment provider’s stock after buying an additional 5,325 shares during the quarter. Edgestream Partners L.P.’s holdings in Masimo were worth $1,393,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. NBC Securities Inc. grew its position in shares of Masimo by 47.1% during the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 73 shares during the period. GAMMA Investing LLC increased its position in Masimo by 75.0% in the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 111 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 200 shares during the period. HHM Wealth Advisors LLC lifted its position in shares of Masimo by 25.0% during the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after buying an additional 125 shares during the last quarter. Finally, Fifth Third Bancorp grew its stake in shares of Masimo by 16.4% during the 2nd quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider’s stock worth $88,000 after acquiring an additional 98 shares during the period. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MASI. Raymond James upgraded Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price objective on the stock in a research note on Wednesday, November 6th. BTIG Research boosted their price target on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Wells Fargo & Company boosted their target price on shares of Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price target (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $167.00.

Masimo Stock Up 1.5 %

Shares of NASDAQ:MASI opened at $174.19 on Wednesday. The company has a market cap of $9.33 billion, a price-to-earnings ratio of 120.13 and a beta of 1.01. Masimo Co. has a one year low of $96.40 and a one year high of $178.27. The firm has a fifty day moving average price of $151.13 and a two-hundred day moving average price of $130.62. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping the consensus estimate of $0.84 by $0.14. The business had revenue of $504.60 million during the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm’s revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.63 earnings per share. Analysts anticipate that Masimo Co. will post 4.03 EPS for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.